[PDF] Top 20 Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

... Gaal 2 1 Division of Diabetes, Nutrition, and Metabolic Disorders, Department of Medicine, CHU Sart Tilman (B35), University of Liège, B-4000 Liège, Belgium 2 Department of Diabetology, Metabolism, ... Voir le document complet

... eradication with IFN-based therapy has a positive effect on the risk for IR ...[61]. An Italian study evaluated non-diabetic GT1–4 HCV-infected patients treated with pegylated IFN + RBV ... Voir le document complet

... of patients on metformin alone. ‡ 27% of patients on metformin ...of patients on metformin ...incretin therapy to manage type 2 diabetes after failure with ... Voir le document complet

... Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analyzed during treatment with dual add-on of dapagliflozin plus saxagliptin ... Voir le document complet

... Administration In the EU, canagliflozin is approved for use as monotherapy (as an adjunct to diet and exercise, when metformin is considered inappropriate) and as an add-on therapy (to ... Voir le document complet

... TRIALS WITH RIMONABANT Metabolic studies In the recent ADAGIO trial, which essentially investigated the effects of rimonabant 20 mg on lipid profile and visceral adipose tissue, ... Voir le document complet

... of Diabetes, Nutrition, and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liège, Liège 4000, Belgium We read with interest the study by Angiolillo et ...that patients ... Voir le document complet

... insulin therapy Seventy-five years after the discovery of insulin, insulin therapy is still controversial in the management of patients with type 2 diabetes so that ... Voir le document complet

... reduction in β-cell function and/or mass, which may hinder remission of diabetes even after marked weight loss if surgery is performed too ...of diabetes remission after bariatric ...Insulin-treated ... Voir le document complet

... agents with different mechanisms of action that offer improved efficacy and/or better tolerability profiles and can be used either as monotherapy or in combination treatment regimens (including ...approved ... Voir le document complet

... measured in agreement with the existing Committee for Proprietary Medicinal Products (CPMP) guidelines ...taken in the supine position using a calibrated mercury sphygmomanometer and an ... Voir le document complet

... both patients and ...by an expert group comprising diabe- tologists and general practitioners, as well as a nurse and a psychologist (the latter two probably having closer relation- ships with ... Voir le document complet

... Aims: Rimonabant, the first selective CB1 receptor blocker, significantly improved HbA1c, fasting glucose, triglycerides, HDL-cholesterol, body weight and waist circumference in a randomised clinical trial ... Voir le document complet

... of type 2 diabetes in high-risk individuals, especially those with IGT ...event in the natural history of T2DM, recent studies have clearly demonstrated that there is an ... Voir le document complet

... loss in overweight or obese type 2 diabetes patients improves lipid profile, blood pressure, and diabetes ...associated with a reduced mortality risk ... Voir le document complet

... profiles in cells, and these changes may persist after return to normo- glycemic ...participate in the acquisi- tion of a cancerous phenotype in these cancer ...skin, with an AGE ... Voir le document complet

... miRNAs in plasma and urine samples across various stages of diabetic nephropathy 16–20 ...available in the relevant literature on its use as a discovery- based approach to identify enriched or dysregulated ... Voir le document complet

... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 weeks resulted ... Voir le document complet

... Supplementary Figure - Relationship between the number of markers of insulin resistance and TMAO concentrations. “HOMA-IR proxy Score” was not associated with TMAO in our dataset (p=0.7362). The following ... Voir le document complet

... that in newly diagnosed type 2 diabetes, the progressive deterioration of blood glucose control over the next 10 years can essentially be explained by a linear decrease of beta-cell insulin ... Voir le document complet